

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Dupilumab for treating moderate to severe prurigo nodularis ID4054

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Sanofi (dupilumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Allergy UK • Eczema Outreach Support • Genetic Alliance UK • National Eczema Society • Nodular Prurigo International • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • British Association of Dermatologists • British Dermatological Nursing Group • British Geriatrics Society • British Society for Cutaneous Allergy • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • St John's Institute of Dermatology • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Hammersmith and Fulham CCG • NHS Liverpool CCG • Welsh Government 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord (cetirizine hydrochloride, citalopram, escitalopram, desloratadine, duloxetine, fluoxetine, loratadine, methotrexate, paroxetine, sertraline, thalidomide, venlafaxine) • ADVANZ Pharma (citalopram, fluoxetine, methotrexate, venlafaxine) • Aspen (azathioprine) • AmaroX (citalopram, duloxetine) • A.Menarini Farmaceutica Internazionale (bilastine, dapoxetine) • Aspire Pharma (duloxetine, rupatadine, venlafaxine)

Provisional stakeholder list for the evaluation of dupilumab for treating moderate to severe prurigo nodularis ID4054

Issue date: November 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 5

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Aurobindo Pharma-Milpharm (cetirizine hydrochloride, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine) • Bayer (loratadine) • Bristol Myers Squibb (cetirizine hydrochloride, thalidomide, venlafaxine) • Brown & Burk (acrivastine, escitalopram, fluoxetine, levocetirizine hydrochloride, loratadine) • Cipla EU (cetirizine hydrochloride, fexofenadine hydrochloride, fluoxetine, methotrexate) • Dexcel Pharma (cetirizine hydrochloride, ciclosporin, venlafaxine) • Dr. Reddy's Laboratories (cetirizine hydrochloride, duloxetine, fexofenadine hydrochloride, fluoxetine, sertraline) • Eli Lilly and Company (duloxetine) • Endo Ventures (fluoxetine) • Fannin / Kent Pharma (fexofenadine hydrochloride, fluoxetine) • Flamingo Pharma (fluoxetine, sertraline) • GlaxoSmithKline (bupropion hydrochloride, cetirizine hydrochloride, paroxetine) • Glenmark Pharmaceuticals Europe (desloratadine, escitalopram, levocetirizine hydrochloride) • Hospira (methotrexate) • Lundbeck (citalopram, escitalopram, vortioxetine) • Lupin Healthcare (sertraline) • Martindale Pharma (venlafaxine) • medac GmbH (methotrexate) • McNeil Products (acrivastine, cetirizine hydrochloride) • Morningside Healthcare (methotrexate, paroxetine, venlafaxine)

Provisional stakeholder list for the evaluation of dupilumab for treating moderate to severe prurigo nodularis ID4054

Issue date: November 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 2 of 5

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Mylan (azathioprine, ciclosporin, desloratadine, fluvoxamine, levocetirizine hydrochloride, sertraline) • Neuraxpharm (duloxetine) • Nordic Pharma (methotrexate) • Nova Laboratories (azathioprine) • Novartis (ciclosporin) • Orexigen Therapeutics Ireland (bupropion hydrochloride) • Organon Pharma (desloratadine) • Orion (methotrexate) • Pfizer (methotrexate) • Pinewood (cetirizine hydrochloride, fluoxetine, loratadine) • Ranbaxy (loratadine, sertraline, venlafaxine) • Rivopharm (citalopram) • Rosemont Pharmaceuticals (fluoxetine, methotrexate, venlafaxine) • Sandoz (citalopram, methotrexate, paroxetine) • Sanofi (fexofenadine hydrochloride, mizolastine) • Santen (ciclosporin) • Sovereign Medical (citalopram, venlafaxine) • Thame Laboratories (citalopram) • The Boots Company (cetirizine hydrochloride, loratadine) • Therakind (methotrexate) • Tillomed Laboratories (azathioprine, duloxetine) • UCB Pharma (cetirizine hydrochloride, levocetirizine hydrochloride) • Upjohn (sertraline, venlafaxine) • Wockhardt (cetirizine hydrochloride) • Zentiva (citalopram, duloxetine, fexofenadine hydrochloride, sertraline) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Epidermo-Epidemiology Society

Provisional stakeholder list for the evaluation of dupilumab for treating moderate to severe prurigo nodularis ID4054

Issue date: November 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 3 of 5

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • British Skin Foundation • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Skin Group • Cochrane UK • Dermatrust • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies

¹ Non company consultees are invited to submit statements relevant to the group they are representing.

that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.